VIRGINIA RETIREMENT SYSTEMS ET Al Sells 20,500 Shares of Supernus Pharmaceuticals, Inc. $SUPN

VIRGINIA RETIREMENT SYSTEMS ET Al cut its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 42.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,236 shares of the specialty pharmaceutical company’s stock after selling 20,500 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.05% of Supernus Pharmaceuticals worth $1,349,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. USA Financial Formulas purchased a new stake in Supernus Pharmaceuticals in the third quarter worth approximately $50,000. EverSource Wealth Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $51,000. Raymond James Financial Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $55,000. Osaic Holdings Inc. grew its holdings in shares of Supernus Pharmaceuticals by 211.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,328 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Supernus Pharmaceuticals by 116.7% in the 2nd quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 1,541 shares during the period.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $49.47 on Friday. The stock has a market cap of $2.84 billion, a P/E ratio of -145.50, a price-to-earnings-growth ratio of 0.47 and a beta of 0.67. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The stock has a 50 day simple moving average of $48.35 and a two-hundred day simple moving average of $43.63.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The business had revenue of $170.00 million for the quarter, compared to the consensus estimate of $175.82 million. During the same quarter in the prior year, the company earned $0.69 EPS. Supernus Pharmaceuticals’s revenue was up 9.3% compared to the same quarter last year. Sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 59,900 shares of the stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $50.57, for a total value of $3,029,143.00. Following the completion of the transaction, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at $61,016,649.46. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Frank Mottola sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the sale, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. The trade was a 56.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 80,610 shares of company stock worth $4,068,895. 8.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research report on Tuesday, September 30th. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Piper Sandler upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. Stifel Nicolaus boosted their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Finally, TD Cowen raised their target price on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $61.60.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.